Christopher P. Cannon, MD, a professor of medicine at Harvard Medical School and senior physician in the Cardiovascular Division at Brigham and Women’s Hospital, spoke about the benefit seen in a study of sotagliflozin for patients with acute heart failure.
Christopher P. Cannon, MD, was one of the investigators on the SOLOIST trial, which led to the approval of sotagliflozin, the first dual sodium-glucose cotransporter-1 and -2 (SGLT1/2) inhibitor. Cannon, a professor of medicine at Harvard Medical School and senior physician in the Cardiovascular Division at Brigham and Women’s Hospital, spoke about the benefit seen in the study for patients with acute heart failure.
Transcript
What is the extra benefit of the dual mechanism in the combined SGLT1/2 inhibitor? And what type of patient do you think would benefit the most and what type of patient would not gain any benefit from it?
Well, I think we don’t know, mechanistically, if this patient needs the dual vs the single. I think in clinical care, we always come back to the large clinical trials that had clinical benefit, and then try and use therapies in those type settings. And so for sotagliflozin in the SOLOIST trial, it was the first and largest of them to date, I think—although moderate size—to test this class in patients who had just had an acute heart failure exacerbation or worsening heart failure, and had a huge benefit.
So the number of patients you need to treat to prevent 1 from dying or being rehospitalized is 4, for 9 months, which is unheard of in terms of a benefit. Typically, you know, therapies are 30, 50, 100 patients to treat, to prevent 1 event. The absolute benefit seen in that acute heart failure setting is probably the first place that many of us will turn to use this to try and emulate what was seen in the in the SOLOIST trial. There are data with the other agents in smaller studies suggesting similar type benefits, but not sort of the magnitude that was seen so clearly in the SOLOIST trial overall.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Persistence Pays Off With Zanubrutinib: A Challenging CLL Case With a Prior BTK Inhibitor Failure
May 10th 2024The case of a 77-year-old woman with a long chronic lymphocytic leukemia (CLL) history illustrates the novel use of zanubrutinib as a potential option for some patients who have failed first-generation Bruton tyrosine kinase (BTK) inhibitors and venetoclax.
Read More